Editas Medicine, Inc. EDIT
2.54 USD -0.01 (-0.35%)
Nov 6, 2026, 2:03 PM EST
2.48 Day range 2.63
1.66 52-week range 3.94
- YTD
- +23.95%
- 1 year
- -5.54%
News
benzinga.com Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6 Wells Fargo analyst Yanan Zhu upgrades Editas Medicine (NASDAQ:EDIT) from Equal-Weight to Overweight and raises the price target from $4 to $6.
benzinga.com Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia The trial has received Human Research Ethics Committee (HREC) approval and completed the Clinical Trial Notification (CTN) process with Australia’s Therapeutic Goods Administration (TGA) and has also…
benzinga.com TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
benzinga.com This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.
benzinga.com Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.
benzinga.com Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other stocks posted notable gains and losses.
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
benzinga.com Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.27) by 44.44 percent. This is a 76.19 percent increase over losses of…
benzinga.com Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery forecast. Other companies such as Nexa Resources SA (NEXA) and Moderna Inc (MRNA) also saw gains in…
benzinga.com Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.- benzinga.com Editas Medicine Prices $125M Public Offering Of 55.6M Shares And Warrants At $2.25 Each Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Editas Medicine Launches Public Stock Offering to Raise Capital Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering…- benzinga.com Editas Reports Cholesterol-Lowering Results for Experimental Gene Therapy Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, presented new preclinical data for EDIT-401, its lead in…
- benzinga.com Editas Medicine Announces New Preclinical Data Supporting Continued Advancement Of Its In Vivo Development Candidate, EDIT-401, And Its Potential As A One-Time Treatment For Hyperlipidemia The data is being presented this week at the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Boston, including one oral presentation and two poster presentations, as…
- benzinga.com Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $4 Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $3.5 to $4.
- benzinga.com Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 39.53 percent increase over losses of…
- benzinga.com Editas Medicine To Present New Preclinical Data Demonstrating Progress Of EDIT-401 As Potential Treatment For Hyperlipidemia At Multiple Upcoming Conferences Five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral…
benzinga.com Editas Medicine Says USPTO Upholds PTAB Ruling Favoring Broad Institute In CRISPR Patent Interference Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office…- benzinga.com Editas Medicine Sees USPTO Reaffirm Broad Institute's CRISPR Patent Priority Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office…
- benzinga.com Jones Trading Upgrades Editas Medicine to Buy, Announces $8 Price Target Jones Trading analyst Soumit Roy upgrades Editas Medicine (NASDAQ:EDIT) from Hold to Buy and announces $8 price target.
benzinga.com Editas Medicine Q4 Earnings Assessment - benzinga.com Editas Medicine Q4 EPS $(0.06) Beats $(0.25) Estimate, Sales $24.741M Beat $5.595M Estimate Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.25) by 76.19 percent. This is a 85 percent increase over losses of…
- benzinga.com Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 5.08 percent. This is a 62.67 percent increase over losses of…
- benzinga.com Editas Medicine To Present Data On LDL Cholesterol–Lowering In Vivo Crispr Gene Editing Medicine At American Heart Association Scientific Sessions Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at…
benzinga.com Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.- benzinga.com Editas Medicine To Deliver EDIT-401 Oral Presentation At European Society Of Gene And Cell Therapy Congress, October 7–10, 2025, In Seville, Spain Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming…
benzinga.com My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
benzinga.com Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - benzinga.com HC Wainwright & Co. Reiterates Buy on Editas Medicine, Maintains $5 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Editas Medicine (NASDAQ:EDIT) with a Buy and maintains $5 price target.
benzinga.com Wells Fargo Maintains Equal-Weight on Editas Medicine, Raises Price Target to $4 Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and raises the price target from $3 to $4.- benzinga.com Editas Medicine Announces EDIT-401 As Lead In Vivo Candidate With ~90% LDL-C Reduction And Human Proof-of-Concept By 2026 EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primatesEDIT-401 on track for human proof-of-concept data by end of 2026Strong cash position with operational runway into…
- benzinga.com HC Wainwright & Co. Maintains Buy on Editas Medicine, Raises Price Target to $5 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $3 to $5.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Baird Maintains Outperform on Editas Medicine, Raises Price Target to $6 Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and raises the price target from $4 to $6.
benzinga.com Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For May 12, 2025
- benzinga.com Earnings Scheduled For March 5, 2025
- benzinga.com Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
- benzinga.com Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday.
- benzinga.com Earnings Scheduled For February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
- benzinga.com Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.
- benzinga.com Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.
- benzinga.com Earnings Scheduled For November 3, 2023 Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 - benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
- benzinga.com Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
- benzinga.com Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
- benzinga.com Earnings Scheduled For August 2, 2023 Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimated to report quarterly earnings at $0.37 per share on revenue of $784.53 million.